Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer

References

• National Cancer Institute of Canada: Canadian Cancer Sta-tistics 1996. Toronto, Canada: 1996, 21–23.
   Google Scholar
• Jemal A, Tiwari RC, Murray T et al. Cancer statistics. CA Cancer J Clin 2004; 54: 8–29.
   PubMed Web of Science ®Google Scholar
• Greenberg PA, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combi-nation chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197–2205.
   Google Scholar
• Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974–984.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Valero V, Pusztai L et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001; 6: 133–146.
   Google Scholar
• Hudis CA. Current status and future directions in breast cancer therapy. Clin Breast Cancer 2003; 4: S70–5.
   PubMedGoogle Scholar
• Giordano SH, Buzdar AU, Smith TL et al. Is breast cancer survival improving? Cancer 2004; 100: 44–52.
   Google Scholar
• Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer. Cancer Control 2005; 12: 73–81.
   PubMedGoogle Scholar
• Folkman J. Clinical applications of research on angiogen-esis. N Engl J Med 1995; 333: 1757–1763.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Garber NH, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676.
   PubMed Web of Science ®Google Scholar
• Toi M, Kondo S, Suzuhi H et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Can-cer 1996; 77: 1101–1106.
   Google Scholar
• Price DJ, Miralem T, Jiang S et al. Role of vascular en-dothelial growth factor in stimulation of cellular invasion and sig-naling of breast cancer cells. Cell Growth Differ 2001; 12: 129–135.
   Google Scholar
• Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61: 5407–5414.
   Google Scholar
• Bevacizumab. Anti-VEGF monoclonal antibody, Avastin, rHuMAb VEGF. Drugs R D 2002; 3: 28–30.
   PubMedGoogle Scholar
• Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30: 117–124.
   Google Scholar
• Miller KD, Wang M, Gralow J, et al. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100). Eur J Cancer Supp 2005; 3: 77.
   Google Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regu-larly: metronomic dosing of cytotoxic drugs can target tumor an-giogenesis in mice. J Clin Invest 2000; 105: 1045.
   PubMed Web of Science ®Google Scholar
• Miller KD, Sweeney C, Sledge GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19: 1195–1206.
   PubMed Web of Science ®Google Scholar
• Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: 15–24.
   Google Scholar
• Eberhard A, Chalet S, Goede V et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumor: im-plications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-1393.
   Google Scholar
• Colleoni M, Rocca A, Sandri M et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factors levels. Ann Oncol 2002; 13: 73–80.
   Google Scholar
• Colleoni M, Orlando L, Sanna G et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006; 17: 232–238.
   Google Scholar
• Orlando L, Cardillo A, Ghisini R et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastasic breast cancer. BMC Cancer 2006; 6: 225–231.
   Google Scholar
• Goldenberg MM: Trastuzumab, a recombinant DNA-de-rived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21: 309–18.
   Google Scholar
• Press MF, Jones LA, Godolphin W et al. HER-2/neu oncogene amplification and expression in breast and ovarian can-cers. In Joseph Ragaz (ed): Effects of Therapy on Biology and Kinetics of the Residual Tumor, New York: Wiley-Liss, Inc., Progress in Clinical and Biological Research. 1990; 354A: 209.
   Google Scholar
• Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791–808.
   PubMed Web of Science ®Google Scholar
• Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyro-sine kinases downregulate vascular endothelial growth factor pro-duction by tumor cells in vitro and in vivo. Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523–1530.
   Google Scholar
• Laughner E, Taghavi P, Chiles K et al. HER2 (neu) sig-nalling increases the rate of hypoxia-inducible factor 1 alpha (HIF-lalpha) synthesis: novel mechanism for HIF-1-mediated vas-cular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995–4004.
   Google Scholar
• lzumi Y, Xu L, di Tomaso E et al. Herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279–280.
   Google Scholar
• Klos KS, Zhou X, Lee S et al. Combined trastuzumab and paclitaxel treatment better inhibits erbB2 mediated angiogenesis in breast carcinoma through a more effective inhibition of AKT than either treatment alone. Cancer 2003; 98: 1377–1385.
   Google Scholar
• Koukurakis MI, Simopoulos C, Polychronidis A et al. The effect of trastuzumab/docetaxel combination on breast cancer angiogenesis: dichotomous effect predictable by HIF1a/VEGF pretreatment status? Anticancer Res 2003; 23: 1673–1680.
   Google Scholar
• Pegram M, Chan D, Dichmann RA et al. Phase II com-bined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. San Antonio Breast Cancer Symposium 2006: 301.
   Google Scholar
• Tonini G, Schiavon G, Silletta M et al. Antiangiogenic properties of metronomic chemotherapy in breast cancer. Fu-ture Oncol 2007; 3: 183–90.
   Google Scholar
• Esteva FJ, Sahin AA, Cristofanilli M et al. Molecular prog-nostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 2002; 12: 319–28
   Google Scholar
• Rocca A. Metronomic chemotherapy with capecitabine and oral cyclophosphamide in combination with bevacizumab in metastatic breast cancer (mbc): Evidence of activity of an antian-giogenic treatment. J Clin Oncol, ASCO Annual Meeting Pro-ceedings 2007; 18S: 11501
   Google Scholar
• Burstein HJ, Spigel D, Kindsvogel K et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. San Antonio Breast Cancer Symposium 2005: 4
   Google Scholar
• Munoz R, Shaked Y, Bertolini F et al. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005; 14: 466–79.
   Google Scholar
• Wen XF, Yang G, Mao Wet al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via dis-tinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006; 25: 6986–96.
   Google Scholar
• Garcia-Sáenz JA, Martin M, Puente J et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005; 6: 325–329.
   Google Scholar
• Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–43.
   Google Scholar
• Sandri MT, Johansson HA, Zorzino L et al. Serum EGFR and serum HER-2/neu are useful predictive and prognostic mark-ers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer 2007; 110: 509–17.
   Google Scholar
• Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13: 31–36.
   Google Scholar
• Bottini A, Generali D, Brizzi MP et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 2006; 24: 3623–8.
   Google Scholar
• ” Relf M, LeJeune S, Scout PA, et al. Expression of the an-giogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963.
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in breast cancer. In Bland KI, Copeland EM III (eds): The breast: comprehensive management of benign and malignant disorders, vol. 1, 3rd ed. St. Louis: WB Saunders, 2004: 563.
   Google Scholar
• Mancuso P, Colleoni M, Calleri A et al. Circulating en-dothelial cell kinetics and viability predict survival in breast can-cer patients receiving metronomic chemotherapy. Blood 2006; 108: 452–459.
   Google Scholar
• Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232–9.
   Google Scholar
• Ranieri G, Patruno R, Ruggieri E et al. Vascular endothe-lial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-57.
   Google Scholar
• Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215–21.
   PubMed Web of Science ®Google Scholar
• Lemieux J, Maunsell E, Provencher L. Chemotherapy-in-duced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 2007, in press.
   Google Scholar